Entero Healthcare Solutions Limited has informed the Exchange regarding Allotment of 7240 Shares.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions held its Board Meeting on May 25, 2026, approving the audited standalone (Revenue: Rs 3,482 Mn, PAT: Rs 269 Mn) and consolidated (Revenue: Rs 65,912 Mn, PAT: Rs 1,458 Mn) financial results for FY ended March 31, 2026, with unmodified audit opinion. The Board also allotted 7,240 equity shares to employees upon exercise of vested options under the Entero Employee Stock Option Plan 2023 (aggregate Rs 2.80 Mn at a premium of Rs 794/share), and separately granted 7,300 fresh ESOPs to employees. Three Non-Executive Independent Directors were approved for re-appointment for a second five-year term (Aug 2026–Aug 2031), subject to shareholder approval at the 8th AGM scheduled for August 19, 2026. An internal auditor was reappointed, and the Board approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through subsidiary Sai Pharma Distributors Private Limited via slump sale. Consolidated PBT for FY2026 stood at Rs 1,793 Mn, up from Rs 1,387 Mn in FY2025.
Steady FY2026 performance with strong consolidated revenue and profit growth, driven partly by multiple acquisitions made during the year. ESOP allotment (7,240 shares) and fresh grant (7,300 options) reflect ongoing employee retention focus. The acquisition of Vishal Surgicals signals continued expansion of distribution network.